EHMT2-Mediated Transcriptional Reprogramming Drives Neuroendocrine Transformation in Non–Small Cell Lung Cancer

Researchers developed preclinical neuroendocrine (NE) transformation models. Next, they identified a transcriptional reprogramming mechanism that drove resistance to erlotinib in NE transformation cell lines and cell-derived xenograft mice.